Castle Biosciences, Inc.

Castle Biosciences, Inc. stands at the forefront of biotechnology research, dedicated to improving health outcomes through innovative diagnostic tests that guide and personalize patient care. With a strong commitment to patients, clinicians, employees, and investors, Castle Biosciences is transforming disease management across a spectrum of critical illnesses. Castle Biosciences markets five proprietary tests meticulously designed to address pressing clinical questions and overcome treatment challenges faced by physicians in dermatologic cancers, Barrett’s esophagus, and uveal melanoma.

Operating from its primary location at 505 S Friendswood Dr, Suite 401, Friendswood, Texas 77546, US, and with laboratory operations in Phoenix, AZ, and Pittsburgh, PA, Castle Biosciences continues to innovate in the realm of precision medicine. Its portfolio includes DecisionDx®-Melanoma, a gene expression profile (GEP) test predicting metastasis or recurrence risk in cutaneous melanoma; DecisionDx®-SCC, predicting metastasis risk in cutaneous squamous cell carcinoma; MyPath® Melanoma, aiding in characterizing suspicious pigmented lesions; TissueCypher® Barrett’s Esophagus, predicting esophageal cancer development; and DecisionDx®-UM, the standard of care for uveal melanoma staging. Castle Biosciences is dedicated to pioneering diagnostic solutions that enhance patient care and improve lives.

Castle Biosciences, Inc. is committed to expanding its impact on healthcare through continuous innovation and a patient-centric approach. By providing clinicians with advanced diagnostic tools, Castle Biosciences empowers them to make informed decisions, leading to better patient outcomes and a healthier future. We invite the management team at Castle Biosciences to create a customized and exclusive company showcase and product listing on our platform, further highlighting your contributions to the field of biotechnology.